Concurrent muscle and bone deterioration in a murine model of cancer cachexia

Physiological Reports

Volumn 1, Issue 6, 2013, Pages 1-9

  Choi, Eunhi ^a,b   Carruthers, Kadir ^a   Zhang, Li ^c   Thomas, Nathan ^a   Battaglino, Ricardo A ^c   Morse, Leslie R ^a,c   Widrick, Jeffrey J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Hallym University College of Medicine   (South Korea)

^c FORSYTH INSTITUTE   (United States)

Author keywords

Body composition; Bone mineral density; Muscle function; Muscle strength

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY MASS; BONE DENSITY; BONE DISEASE; BREATHING MUSCLE; CACHEXIA; CALORIC INTAKE; CONTROLLED STUDY; DETERIORATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EXTENSOR DIGITORUM LONGUS MUSCLE; HINDLIMB MUSCLE; LEAN BODY WEIGHT; LEWIS LUNG CARCINOMA CELL; MALE; MOUSE; MUSCLE DISEASE; MUSCLE MASS; MUSCLE TETANIC CONTRACTION; NONHUMAN; SOLEUS MUSCLE; TUMOR MODEL; TUMOR VOLUME;

EID: 85008970151     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.1002/phy2.144     Document Type: Article

References (40)

1. Acharyya, S., K. J. Ladner, L. L. Nelsen, J. Damrauer, P. J. Reiser, S. Swoap, et al. 2004. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 114: 370–378.
2. Acharyya, S., M. E. Butchbach, Z. Sahenk, H. Wang, M. Saji, M. Carathers, et al. 2005. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 8: 421–432.
3. Agbulut, O., P. Noirez, F. Beaumont, and G. Butler-Browne. 2003. Myosin heavy chain isoforms in postnatal muscle development of mice. Biol. Cell 95: 399–406.
4. Andrade, F. H., M. B. Reid, D. G. Allen, and H. Westerblad. 1998. Effect of hydrogen peroxide and dithiothreitol on contractile function of single skeletal muscle fibres from the mouse. J. Physiol. 509: 565–575.
5. Argiles, J. M., M. Figueras, E. Ametller, G. Fuster, M. Olivan, C. C. de Oliveira, et al. 2008. Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle Nerve 37: 190–195.
6. Aulino, P., E. Berardi, V. M. Cardillo, E. Rizzuto, B. Perniconi, C. Ramina, et al. 2010. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer 10: 363.
7. Azouz, S. M., J. Walpole, S. Amirifeli, K. N. Taylor, M. W. Grinstaff, and Y. L. Colson. 2008. Prevention of local tumor growth with paclitaxel-loaded microspheres. J. Thorac. Cardiovasc. Surg. 135: 1014–1021.
8. Baltgalvis, K. A., F. G. Berger, M. M. Pena, J. M. Davis, and J. A. Carson. 2008. Effect of exercise on biological pathways in ApcMin/+ mouse intestinal polyps. J. Appl. Physiol. 104: 1137–1143.
9. Banduseela, V., J. Ochala, K. Lamberg, H. Kalimo, and L. Larsson. 2007. Muscle paralysis and myosin loss in a patient with cancer cachexia. Acta Myol. 26: 136–144.
10. Benny Klimek, M. E., T. Aydogdu, M. J. Link, M. Pons, L. G. Koniaris, and T. A. Zimmers. 2010. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391: 1548–1554.
11. Brooks, S. V., and J. A. Faulkner. 1988. Contractile properties of skeletal muscles from young, adult and aged mice. J. Physiol. 404: 71–82.
12. Buck, M., and M. Chojkier. 1996. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J. 15: 1753–1765.
13. Busquets, S., M. T. Figueras, G. Fuster, V. Almendro, R. Moore-Carrasco, E. Ametller, et al. 2004. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res. 64: 6725–6731.
14. Cai, D., J. D. Frantz, N. E. Tawa Jr., P. A. Melendez, B. C. Oh, H. G. Lidov, et al. 2004. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119: 285–298.
15. Diffee, G. M., K. Kalfas, S. Al-Majid, and D. O. McCarthy. 2002. Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am. J. Physiol. Cell Physiol. 283: C1376–C1382.
16. Faulkner, J. A., S. V. Brooks, and R. G. Dennis. 1999. Measurement of recovery of function following whole muscle transfer, myoblast transfer, and gene therapy. Methods Mol. Med. 18: 155–172.
17. Fearon, K. C. 1992. The mechanisms and treatment of weight loss in cancer. Proc. Nutr. Soc. 51: 251–265.
18. Gorselink, M., S. F. Vaessen, L. G. van der Flier, I. Leenders, D. Kegler, E. Caldenhoven, et al. 2006. Mass-dependent decline of skeletal muscle function in cancer cachexia. Muscle Nerve 33: 691–693.
19. Hardin, B. J., K. S. Campbell, J. D. Smith, S. Arbogast, J. Smith, J. S. Moylan, et al. 2008. TNF-alpha acts via TNFR1 and muscle-derived oxidants to depress myofibrillar force in murine skeletal muscle. J. Appl. Physiol. 104: 694–699.
20. Inagaki, J., V. Rodriguez, and G. P. Bodey. 1974. Proceedings: causes of death in cancer patients. Cancer 33: 568–573.
21. Kandarian, S. 2008. The molecular basis of skeletal muscle atrophy–parallels with osteoporotic signaling. J. Musculoskelet. Neuronal Interact. 8: 340–341.
22. Kim, H. Y., C. Alarcon, S. Pourteymour, J. E. Wergedal, and S. Mohan. 2013. Disruption of claudin-18 diminishes ovariectomy-induced bone loss in mice. Am. J. Physiol. Endocrinol. Metab. 304: E531–E537.
23. Llovera, M., C. Garcia-Martinez, J. Lopez-Soriano, N. Agell, F. J. Lopez-Soriano, I. Garcia, et al. 1998a. Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Lett. 130: 19–27.
24. Llovera, M., C. Garcia-Martinez, J. Lopez-Soriano, N. Carbo, N. Agell, F. J. Lopez-Soriano, et al. 1998b. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol. Cell. Endocrinol. 142: 183–189.
25. Mayo, J. G. 1972. Biologic characterization of the subcutaneously implanted Lewis lung tumor. Cancer Chemother. Rep. 2: 325–330.
26. Mendell, J. R., and W. K. Engel. 1971. The fine structure of type II muscle fiber atrophy. Neurology 21: 358–365.
27. Mendez, J., and A. Keys. 1960. Density and composition of mammalian muscle. Metabolism 9: 184–188.
28. Murphy, K. T., A. Chee, B. G. Gleeson, T. Naim, K. Swiderski, R. Koopman, et al. 2011. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 301: R716–R726.
29. Nicholson, J. R., G. Kohler, F. Schaerer, C. Senn, P. Weyermann, and K. G. Hofbauer. 2006. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J. Pharmacol. Exp. Ther. 317: 771–777.
30. Petrof, B. J., J. B. Shrager, H. H. Stedman, A. M. Kelly, and H. L. Sweeney. 1993. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA 90: 3710–3714.
31. Prochniewicz, E., D. A. Lowe, D. J. Spakowicz, L. Higgins, K. O’conor, L. V. Thompson, et al. 2008. Functional, structural, and chemical changes in myosin associated with hydrogen peroxide treatment of skeletal muscle fibers. Am. J. Physiol. Cell Physiol. 294: C613–C626.
32. Reid, M. B., J. Lannergren, and H. Westerblad. 2002. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am. J. Respir. Crit. Care Med. 166: 479–484.
33. Rybakova, I. N., J. R. Patel, and J. M. Ervasti. 2000. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J. Cell Biol. 150: 1209–1214.
34. Spatz, J. M., R. Ellman, A. M. Cloutier, L. Louis, M. van Vliet, L. J. Suva, et al. 2013. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J. Bone Miner. Res. 28: 865–874.
35. Stevens, E. D., and J. A. Faulkner. 2000. The capacity of mdx mouse diaphragm muscle to do oscillatory work. J. Physiol. 522: 457–466.
36. Taylor, J. A., and S. C. Kandarian. 1994. Advantage of normalizing force production to myofibrillar protein in skeletal muscle cross-sectional area. J. Appl. Physiol. (1985) 76: 974–978.
37. Tisdale, M. J. 2009. Mechanisms of cancer cachexia. Physiol. Rev. 89: 381–410.
38. Widrick, J. J., S. Jiang, S. J. Choi, S. T. Knuth, and P. A. Morcos. 2011. An octaguanidine-morpholino oligo conjugate improves muscle function of mdx mice. Muscle Nerve 44: 563–570.
39. Wilcox, P. G., Y. Wakai, K. R. Walley, D. J. Cooper, and J. Road. 1994. Tumor necrosis factor alpha decreases in vivo diaphragm contractility in dogs. Am. J. Respir. Crit. Care Med. 150: 1368–1373.
40. Wyke, S. M., S. T. Russell, and M. J. Tisdale. 2004. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br. J. Cancer 91: 1742–1750